Overview

Comparison of Treatment rOutine Using afLibERcept: Strict vs relAxed retreatmeNT Regimen

Status:
Active, not recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to test non-inferiority of aflibercept "treat and extend" using a relaxed retinal fluid management relative to aflibercept "treat and extend" using a strict retinal fluid management SD-OCT (spectral domain optical coherence tomography) disease activity guided retreatment with respect to best-corrected visual acuity (BCVA) from baseline to end of treatment.
Details
Lead Sponsor:
University Hospital Inselspital, Berne
Treatments:
Aflibercept